We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Renal Retention of Microbubbles

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01647464
Recruitment Status : Completed
First Posted : July 23, 2012
Results First Posted : April 28, 2016
Last Update Posted : April 28, 2016
Sponsor:
Information provided by (Responsible Party):
Jonathan R. Lindner, MD, Oregon Health and Science University

Brief Summary:
Flank pain has been reported with ultrasound (US) contrast agents. The purpose of this study is to determine whether there is retention of ultrasound contrast agents in the renal microcirculation, which has been described in mice.

Condition or disease
- Study Focus: Renal Retention of Lipid Microbubbles

Detailed Description:
In this study patients undergoing clinically indicated contrast echocardiography will have renal ultrasound performed 10 minutes after completion of contrast infusion to determine the presence and location of renal retention of lipid microbubbles.

Study Type : Observational
Actual Enrollment : 10 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Study of Whether There is Renal Retention of Lipid Microbubble Ultrasound Contrast Agents
Study Start Date : July 2012
Primary Completion Date : October 2012
Study Completion Date : October 2012

Group/Cohort
Contrast administration
Patients undergoing contrast-enhanced echo.



Primary Outcome Measures :
  1. Renal Video Intensity Units [ Time Frame: 10 min ]
    Video intensity units in the kidney 10 min after completion of a clinically indicated contrast echocardiography study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing contrast echocardoigraphy
Criteria

Inclusion Criteria:

  • Undergoing clinically indicated contrast echo
  • adequate renal ultrasound images

Exclusion Criteria:

  • chronic inflammatory disease
  • known kidney disease
  • immunomodulatory therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01647464


Locations
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University

Responsible Party: Jonathan R. Lindner, MD, Professor of Medicine, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT01647464     History of Changes
Other Study ID Numbers: MBretention
First Posted: July 23, 2012    Key Record Dates
Results First Posted: April 28, 2016
Last Update Posted: April 28, 2016
Last Verified: March 2016